
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3886131/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nature Communications, 2019, 10, 4666.	12.8	146
2	Germline mutations in the DNA damage response genes <i>BRCA1</i> , <i>BRCA2</i> , <i>BARD1</i> and <i>TP53</i> in patients with therapy related myeloid neoplasms. Journal of Medical Genetics, 2012, 49, 422-428.	3.2	87
3	Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. Journal of Infection, 2018, 77, 235-241.	3.3	78
4	Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. Journal of Infection, 2012, 65, 588-591.	3.3	66
5	Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. Critical Care, 2015, 19, 178.	5.8	65
6	Galactomannan testing and <i>Aspergillus</i> PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Medical Mycology, 2017, 55, myw102.	0.7	65
7	Clinical implications of subclonal <i>TP53</i> mutations in acute myeloid leukemia. Haematologica, 2019, 104, 516-523.	3.5	65
8	Adipose triglyceride lipase acts on neutrophil lipid droplets to regulate substrate availability for lipid mediator synthesis. Journal of Leukocyte Biology, 2015, 98, 837-850.	3.3	64
9	Lineage-instructive function of C/EBPÎ \pm in multipotent hematopoietic cells and early thymic progenitors. Blood, 2010, 116, 4116-4125.	1.4	59
10	Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. International Journal of Molecular Sciences, 2016, 17, 2080.	4.1	58
11	Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia. Clinical Epigenetics, 2021, 13, 1.	4.1	57
12	Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood, 2017, 130, 946-948.	1.4	52
13	Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. Nature Communications, 2014, 5, 5191.	12.8	51
14	Diagnostic accuracy of the <i>Aspergillus</i> â€specific bronchoalveolar lavage lateralâ€flow assay in haematological malignancy patients. Mycoses, 2015, 58, 461-469.	4.0	51
15	A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood, 2005, 105, 3731-3736.	1.4	47
16	Preâ€fibrotic/early primary myelofibrosis vs. WHOâ€defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. American Journal of Hematology, 2017, 92, 885-891.	4.1	47
17	Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica, 2012, 97, 246-250.	3.5	46
18	Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. Cancer Research, 2016, 76, 3644-3654.	0.9	45

#	Article	IF	CITATIONS
19	Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. Blood, 2017, 129, 2587-2591.	1.4	44
20	Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	41
21	Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. Leukemia and Lymphoma, 2018, 59, 501-504.	1.3	41
22	Acute myeloid leukemia with TP53 germ line mutations. Blood, 2016, 128, 2270-2272.	1.4	39
23	Siteâ€5pecific Ubiquitination Determines Lysosomal Sorting and Signal Attenuation of the Granulocyte Colony‣timulating Factor Receptor. Traffic, 2009, 10, 1168-1179.	2.7	31
24	Realâ€world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study. Mycoses, 2018, 61, 201-205.	4.0	27
25	Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination. Lancet, The, 2021, 397, 1842.	13.7	25
26	Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. International Journal of Antimicrobial Agents, 2014, 44, 140-144.	2.5	24
27	SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban. Lancet, The, 2021, 397, e19.	13.7	23
28	High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34â€positive AML. Cancer Medicine, 2019, 8, 1771-1778.	2.8	22
29	Serum and urine galactomannan testing for screening in patients with hematological malignancies. Medical Mycology, 2014, 52, 647-652.	0.7	21
30	Urine Galactomannan-to-Creatinine Ratio for Detection of Invasive Aspergillosis in Patients with Hematological Malignancies. Journal of Clinical Microbiology, 2016, 54, 771-774.	3.9	20
31	Evidence for a role of decitabine in the treatment of myeloid sarcoma. Annals of Hematology, 2017, 96, 505-506.	1.8	20
32	Successful management of vaccine-induced immune thrombotic thrombocytopenia-related cerebral sinus venous thrombosis after ChAdOx1 nCov-19 vaccination. Stroke and Vascular Neurology, 2021, , svn-2021-001142.	3.3	20
33	Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection. Frontiers in Immunology, 2019, 10, 1798.	4.8	19
34	Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies. Clinical Cancer Research, 2018, 24, 1103-1113.	7.0	18
35	Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis. Leukemia Research, 2016, 42, 47-51.	0.8	17
36	Chemotherapy-Induced Intestinal Mucosal Barrier Damage: a Cause of Falsely Elevated Serum 1,3-Beta- <scp>d</scp> -Glucan Levels?. Journal of Clinical Microbiology, 2016, 54, 798-801.	3.9	17

#	Article	IF	CITATIONS
37	Prognostic potential of 1,3-beta-d-glucan levels in bronchoalveolar lavage fluid samples. Journal of Infection, 2016, 72, 29-35.	3.3	16
38	Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. American Journal of Hematology, 2018, 93, 23-30.	4.1	16
39	Detection of (1→3)â€Î²â€ <scp>D</scp> â€glucan in sameâ€day urine and serum samples obtained from patients haematological malignancies. Mycoses, 2015, 58, 394-398.	with 4.0	13
40	Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1186-1192.	2.0	13
41	Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometryâ€based leukemic cell enrichment followed by mutational profiling. American Journal of Hematology, 2020, 95, 1148-1157.	4.1	13
42	Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia. Cancers, 2020, 12, 496.	3.7	12
43	Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data. Blood Cancer Journal, 2017, 7, 643.	6.2	11
44	Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. Haematologica, 2020, 105, 375-386.	3.5	11
45	Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration. Blood, 2018, 131, 826-830.	1.4	10
46	Feasibility and safety of using an automated decision support system for insulin therapy inÂthe treatment of steroidâ€induced hyperglycemia in patients with acute graftâ€versusâ€host disease: A randomized trial. Journal of Diabetes Investigation, 2019, 10, 339-342.	2.4	8
47	Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. Wiener Klinische Wochenschrift, 2017, 129, 293-302.	1.9	6
48	Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia. Annals of Hematology, 2015, 94, 1923-1924.	1.8	5
49	Ruxolitinib therapy for myelofibrosis in Austria. Wiener Klinische Wochenschrift, 2018, 130, 495-504.	1.9	5
50	Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations. Annals of Hematology, 2022, 101, 837-846.	1.8	5
51	Detection of AML-specific TP53 mutations in bone marrow–derived mesenchymal stromal cells cultured under hypoxia conditions. Annals of Hematology, 2019, 98, 2019-2020.	1.8	4
52	Myeloid sarcoma in the oral cavity. International Journal of Stomatology & Occlusion Medicine, 2013, 6, 65-69.	0.1	3
53	Austrian recommendations for the management of polycythemia vera. Wiener Klinische Wochenschrift, 2018, 130, 535-542.	1.9	3
54	The role of germline mutation profiling in the selection of related donors for haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1502-1505.	2.4	3

#	Article	IF	CITATIONS
55	TNFα Rescues Dendritic Cell Development in Hematopoietic Stem and Progenitor Cells Lacking C/EBPα. Cells, 2020, 9, 1223.	4.1	3
56	EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity. Leukemia, 2021, 35, 1521-1526.	7.2	3
57	Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio. ESC Heart Failure, 2021, 8, 3397-3402.	3.1	3
58	Red blood cell morphology in patients with β-thalassemia minor. Laboratoriums Medizin, 2017, 41, 49-52.	0.6	2
59	Austrian recommendations for the management of essential thrombocythemia. Wiener Klinische Wochenschrift, 2021, 133, 52-61.	1.9	2
60	Characterization of a Juxtamembrane Lysine as a Determinant in Lysosomal Routing and Signal Downregulation of the Activated G-CSF Receptor (G-CSFR) Blood, 2007, 110, 2190-2190.	1.4	2
61	miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms. Annals of Hematology, 2021, 100, 2845-2847.	1.8	1
62	The frequency of occurrence of fish-shaped red blood cells in different haematologic disorders. Clinical Chemistry and Laboratory Medicine, 2018, 56, 323-326.	2.3	0
63	AÂmulticenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in aÂreal-life setting. Wiener Klinische Wochenschrift, 2020, 132, 415-422.	1.9	0
64	Lineage Instructive Function of C/EBPα in Multipotent Hematopoietic Progenitor Cells Revealed in a Novel Cebpa-Cre Knock-in Model. Blood, 2008, 112, 2458-2458.	1.4	0